The Fast Company Executive Board is a private, fee-based network of influential leaders, experts, executives, and entrepreneurs who share their insights with our audience. BY Guy Yehiav In the U.S., ...

Clinical trial attrition can be detrimental to clinical outcomes, patient well-being and the financial health of research programs. Clinical trial dropout rates, which range from 15% to 40%, greatly ...

Health care is undergoing an important and well-needed shift from a one-size-fits-all approach to more personalized, precise, patient-focused care. A similar approach needs to be implemented at scale ...

In today's fast-paced and ever-evolving landscape of clinical trials, the ability to efficiently analyze and visualize data has become paramount. The vast amounts of data generated from these trials ...

Expanding clinical trial access locally reduces logistical and financial barriers, making participation feasible for underserved populations. Addressing myths about clinical trials helps patients ...

In today’s globalized pharma environment, technical and supply chain challenges in the clinical trial process create ripple effects felt by stakeholders across regions and functions. This has created ...

Already since 31 January 2023 all applications for new clinical trials must be submitted under the legal framework of the Clinical Trials Regulation (Regulation EU/536/2014, CT Regulation). By 31 ...